Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Phase I clinical study to begin with Reolysin as cancer treatment

March 27, 2000

No Comments

FDA grants orphan drug status to Zadaxin for treatment of liver cancer

March 24, 2000

No Comments

Phase I study of AltaRex's BrevaRex MAb completed

March 22, 2000

No Comments

StressGen initiates phase II study with HspE7 in high-grade cervical dysplasia

March 22, 2000

No Comments

FDA's ODAC recommends approval of Mylotarg for relapsed AML

March 21, 2000

No Comments

Picower Institute presents new immunotherapeutic anticancer agents

March 17, 2000

No Comments

Antisoma takes up another product from ICRF for clinical development

March 17, 2000

No Comments

Low-dose M-Vax shows promise in stage III metastatic melanoma

March 17, 2000

No Comments

Seattle Genetics updates MAb program

March 17, 2000

No Comments

IND filed by NeoPharm for glioblastoma treatment

March 16, 2000

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Immuno-oncology
RSS

Phase I clinical study to begin with Reolysin as cancer treatment

FDA grants orphan drug status to Zadaxin for treatment of liver cancer

Phase I study of AltaRex's BrevaRex MAb completed

StressGen initiates phase II study with HspE7 in high-grade cervical dysplasia

FDA's ODAC recommends approval of Mylotarg for relapsed AML

Picower Institute presents new immunotherapeutic anticancer agents

Antisoma takes up another product from ICRF for clinical development

Low-dose M-Vax shows promise in stage III metastatic melanoma

Seattle Genetics updates MAb program

IND filed by NeoPharm for glioblastoma treatment

Today's news in brief

Today's news in brief

STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

AI drives financings, approvals for APAC med-tech in 2024

Immuno-oncology RSS

Immuno-oncology
RSS